Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease

作     者：Jean-Claude Trinchet Nathalie Ganne-Carrié Pierre Nahon Gisèle N’kontchou Michel Beaugrand 

作者机构：Service d'Hépato-Gastroentérologie Hpital Jean Verdier Assistance Publique-Hpitaux de Paris UPRES EA 3409 and UPRES EA 3410 UFR SMBH Université Paris 13 Bondy France 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2007年第13卷第17期

页      面：2455-2460页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 100214[医学-肿瘤学] 10[医学] 

主　　题：Hepatocellular carcinoma Cirrhosis Hepatitis C virus Epidemiology Screening Treatment Prevention 

摘      要：Hepatitis C virus (HCV) is a major cause of hepatocellular carcinoma (HCC) worldwide due to the high prevalence of HCV infection and the high rate of HCC occurrence in patients with HCV cirrhosis. A striking increase in HCC incidence has been observed during the past decades in most industrialized countries, partly related to the growing number of patients infected by HCV. HCC is currently the main cause of death in patients with HCV-related cirrhosis, a fact that justifies screening as far as curative treatments apply only in patients with small tumors. As a whole, treatment options are similar in patients with cirrhosis whatever the cause. Chemoprevention could be also helpful in the near future. It is strongly suggested that antiviral treatment of HCV infection could prevent HCC occurrence, even in cirrhotic patients, mainly when a sustained virological response is obtained.